

Ref: MHL/Sec&Legal/2020-21/109

Date: June 24, 2020

To,  
**Head, Listing Compliance Department  
BSE Limited**  
Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Head Listing Compliance Department  
National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

**Scrip Code: 542650**

**Scrip Symbol: METROPOLIS**

Dear Sir / Madam,

**Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")**

This is to inform you that a member of the Promoter Group of the Company has divested 3,054,545 equity shares of the Company constituting 6.03% of the issued and paid-up share capital of the Company through a bulk deal transaction on the Stock Exchanges today.

Post this divestment, the Promoter along with the Promoter Group holding in the Company would constitute 50.81% of the paid up capital of the Company, which was 56.84% before the above stake divestment.

Please find enclosed a press release in this regard by the Promoter of the Company.

Please take the above on record.

Yours Faithfully,

For **Metropolis Healthcare Limited**

Poonam Tanwani  
**Company Secretary & Compliance Officer**  
Membership No. A19182

Encl: a/a

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**

**METROPOLIS**  
The Pathology Specialist

**Metropolis Healthcare Limited**

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.  
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)

Website: [www.metropolisindia.com](http://www.metropolisindia.com)

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

**Member of the Promoter Group executes share sale through block deal;  
Sale proceeds to be utilized to substantially reduce Promoter debt and  
release pledge of shares**

**Snapshot of the share sale through block deal**

- 3,054,545 shares of Metropolis Healthcare Limited (“**Company**”) sold at Rs. 1,383.44 per equity share
- Price was at a marginal 4.75% discount to the closing price of the stock on BSE on 23<sup>rd</sup> June 2020
- Promoter and promoter group holding post stake sale stands at 50.81% from 56.84% in the Company
- The value of the Proceeds is Rs. 422.58 Crores; Significant Debt to be reduced by Promoter Group

Mumbai, June 24, 2020: Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider is informed by the member of Promoter and Promoter Group that a share sale trade has been executed today through a block trade. 3,054,545 shares of the Company have been sold at a price of Rs. 1,383.44 per equity share amounting to Rs. 422.58 crores as sale proceeds.

The proceeds from this divestment are intended to be used for substantial repayment of the loan availed by Metz Advisory LLP. The pledge of equity shares of the Company created in favor of the lenders by Metz Advisory LLP, Ameera Shah, Dr. Sushil Shah and Dr. Duru Sushil Shah, will proportionately be released by the lenders to the extent of the repayment, in terms of the loan arrangement.

We believe that the reduction of pledge of equity shares by Metz Advisory LLP, Ameera Shah, Dr. Sushil Shah and Dr. Duru Sushil Shah by substantial repayment of the loan availed by Metz Advisory LLP, is in the overall interests of all the stakeholders.

“We have sold a small part of our holding today, in line with our commitment to bring down debt and associated pledges at the Promoter and Promoter Group level. The book building saw strong demand from institutions both Domestic and International. Existing as well as New holders have purchased the shares. The share sale happened at a marginal discount and saw interest from Institutional Investors thus reposing their confidence and the faith in Metropolis story, its promoters and senior Management Team.

We are an organization with a strong sense of purpose and are committed to solid governance framework and sound accounting policies. In addition to creating value for all stakeholders we will continue to walk the extra mile for our patients who trust us during their most anxious moments during illness.”

**Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.**

**About Metropolis:** Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade; which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

**Safe harbor statement**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For further details please contact:**

Company	Investor Relations Advisors:
 <p>Metropolis Healthcare Ltd. CIN -L73100MH2000PLC192798</p>	 <p>Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285</p>
<p><b>Ms. Nadhiya Mali – Corporate Communications</b>  <a href="mailto:nadhiya.mali@metropolisindia.com">nadhiya.mali@metropolisindia.com</a>            +91-8879009517   <a href="http://www.metropolisindia.com">www.metropolisindia.com</a></p>	<p><b>Mr. Shogun Jain / Mr. Sagar Shroff</b>  <a href="mailto:shogun.jain@sgapl.net">shogun.jain@sgapl.net</a> / <a href="mailto:sagar.shroff@sgapl.net">sagar.shroff@sgapl.net</a>            +91-77383 77756 / +91-9820519303   <a href="http://www.sgapl.net">www.sgapl.net</a></p>